📊 RXRX Key Takeaways
Is Recursion Pharmaceuticals, Inc.. (RXRX) a Good Investment?
Recursion Pharmaceuticals is a pre-profitability biotech company with severe operating losses (-$128.5M) relative to minimal revenue ($6.5M), indicating an unsustainable business model in the near term. While the balance sheet is strong with $654.5M in cash and minimal debt providing 8+ years of runway, the -$81.1M annual operating cash burn and negative gross profit model present fundamental concerns. Success depends entirely on unproven clinical pipeline execution.
Recursion Pharmaceuticals, Inc.. Key Strengths (RXRX)
- Strong cash position of $654.5M with minimal debt ($7.2M) providing substantial operational runway
- Excellent liquidity ratios (5.47x current/quick) indicating strong ability to meet short-term obligations
- Positive revenue growth of 26.9% YoY, demonstrating early commercial traction despite tiny absolute base
RXRX Stock Risks: Recursion Pharmaceuticals, Inc.. Investment Risks
- Severe cash burn of $81.1M annually with current revenue of only $6.5M creates deeply unprofitable operations
- Operating margin of -1985.6% indicates company is far from profitability and dependent on pipeline success
- Clinical development and regulatory approval risks inherent to pharmaceutical sector with unproven pipeline as only path to viability
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue growth trajectory and near-term commercialization milestones
- Operating loss trend and progress toward gross margin profitability
Recursion Pharmaceuticals, Inc.. (RXRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.47x current ratio provides a solid financial cushion.
RXRX Profit Margin, ROE & Profitability Analysis
RXRX vs Healthcare Sector: How Recursion Pharmaceuticals, Inc.. Compares
How Recursion Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Recursion Pharmaceuticals, Inc.. Stock Overvalued? RXRX Valuation Analysis 2026
Based on fundamental analysis, Recursion Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Recursion Pharmaceuticals, Inc.. Balance Sheet: RXRX Debt, Cash & Liquidity
RXRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Recursion Pharmaceuticals, Inc..'s revenue has grown significantly by 634% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.58 indicates the company is currently unprofitable.
RXRX Revenue Growth, EPS Growth & YoY Performance
RXRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.5M | -$117.5M | $-0.22 |
| Q3 2025 | $5.2M | -$95.8M | $-0.34 |
| Q2 2025 | $14.4M | -$97.5M | $-0.40 |
| Q1 2025 | $13.8M | -$91.4M | $-0.39 |
| Q3 2024 | $10.5M | -$93.0M | $-0.34 |
| Q2 2024 | $11.0M | -$76.7M | $-0.38 |
| Q1 2024 | $12.1M | -$65.3M | $-0.34 |
| Q3 2023 | $10.5M | -$60.4M | $-0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Recursion Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
RXRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Recursion Pharmaceuticals, Inc.. (CIK: 0001601830)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780693380.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780693375.xml | View → |
| Jun 4, 2026 | 4 | xslF345X06/wk-form4_1780607095.xml | View → |
| Jun 4, 2026 | 4 | xslF345X06/wk-form4_1780607089.xml | View → |
| May 27, 2026 | 4 | xslF345X06/wk-form4_1779912912.xml | View → |
❓ Frequently Asked Questions about RXRX
What is the AI rating for RXRX?
Recursion Pharmaceuticals, Inc.. (RXRX) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RXRX's key strengths?
Claude: Strong cash position of $654.5M with minimal debt ($7.2M) providing substantial operational runway. Excellent liquidity ratios (5.47x current/quick) indicating strong ability to meet short-term obligations.
What are the risks of investing in RXRX?
Claude: Severe cash burn of $81.1M annually with current revenue of only $6.5M creates deeply unprofitable operations. Operating margin of -1985.6% indicates company is far from profitability and dependent on pipeline success.
What is RXRX's revenue and growth?
Recursion Pharmaceuticals, Inc.. reported revenue of $6.5M.
Does RXRX pay dividends?
Recursion Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find RXRX SEC filings?
Official SEC filings for Recursion Pharmaceuticals, Inc.. (CIK: 0001601830) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RXRX's EPS?
Recursion Pharmaceuticals, Inc.. has a diluted EPS of $-0.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RXRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Recursion Pharmaceuticals, Inc.. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RXRX stock overvalued or undervalued?
Valuation metrics for RXRX: ROE of -11.5% (sector avg: 15%), net margin of -1,815.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RXRX's AI grade for 2026?
Our dual AI analysis gives Recursion Pharmaceuticals, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RXRX's free cash flow?
Recursion Pharmaceuticals, Inc..'s operating cash flow is $-81.1M, with capital expenditures of $258.0K. FCF margin is -1,257.1%.
How does RXRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,815.6% (avg: 12%), ROE -11.5% (avg: 15%), current ratio 5.47 (avg: 2).